Alkem Laboratories Limited has informed the Exchange about Amalgamation/Merger
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories' Board has approved the merger of its wholly-owned subsidiary Adroit Biomed Limited (ABL) into itself under Sections 230-232 of the Companies Act, 2013. Since ABL is fully owned by Alkem, no consideration will be paid, no shares will be issued, and there is no share exchange ratio. The shareholding pattern of Alkem will remain unchanged after the merger. ABL is a small entity with revenue of about INR 596.8 million and net worth of INR 75.7 million as of March 31, 2025, compared to Alkem's revenue of INR 88,134.4 million and net worth of INR 1,23,218.3 million. The merger is subject to approval from the NCLT Mumbai bench, shareholders, and creditors. The rationale is to simplify the group structure, reduce duplication, cut overheads, and achieve operational efficiencies.
This is a routine internal restructuring of a small wholly-owned subsidiary and is unlikely to have a material impact on Alkem's financials or share price. Shareholders should see no change in their holdings, but may benefit from lower administrative costs and a cleaner group structure over the long term.